Carsten Denkert

Carsten Denkert's AcademicInfluence.com Rankings

Carsten Denkert

Biology

#7145

World Rank

#10016

Historical Rank

Computational Biology

#131

World Rank

#131

Historical Rank

Molecular Biology

#792

World Rank

#812

Historical Rank

Biochemistry

#967

World Rank

#1078

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Carsten Denkert Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Carsten Denkert's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients (2010) (2407)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012) (1966)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. (2010) (1377)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) (1032)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. (2018) (1030)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization (2012) (950)
Pembrolizumab for Early Triple-Negative Breast Cancer. (2020) (929)
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. (2015) (800)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. (2014) (751)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic (2016) (602)
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies (2017) (484)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy (2008) (462)
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. (2012) (457)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. (2015) (456)
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. (2011) (441)
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer (2012) (412)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2015) (385)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. (2006) (363)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. (2019) (360)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) (345)
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo (2008) (342)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. (2008) (328)
Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover (2008) (304)
CD24 expression is a new prognostic marker in breast cancer. (2003) (302)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. (2016) (284)
Expression of cyclooxygenase 2 in human malignant melanoma. (2001) (284)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) (281)
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. (2002) (274)
Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. (2019) (271)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2017) (270)
Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study (2010) (267)
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma (2003) (245)
Response-guided neoadjuvant chemotherapy for breast cancer. (2013) (232)
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (2014) (222)
Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach (2012) (220)
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer (2008) (218)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer (2018) (215)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma (2015) (211)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) (207)
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. (2002) (204)
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression (2013) (196)
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. (2013) (193)
The landscape of metastatic progression patterns across major human cancers (2014) (192)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy (2016) (189)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial (2013) (187)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. (2019) (183)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto (2018) (182)
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group (2015) (182)
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients (2003) (177)
Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer (2012) (176)
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma (2004) (175)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
Breast cancer (2021) (174)
Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression (2004) (171)
Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades (2004) (170)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy (2011) (170)
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. (2009) (167)
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. (2010) (165)
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer (2008) (164)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (2022) (164)
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. (2015) (163)
Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma (2004) (163)
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2 (2006) (161)
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations (2006) (159)
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. (2008) (157)
Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. (2015) (157)
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival (2005) (156)
High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis (2007) (153)
Strategies for developing Ki67 as a useful biomarker in breast cancer. (2015) (145)
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications (2005) (142)
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. (2013) (136)
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer (2016) (133)
Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. (2012) (132)
Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study (2012) (129)
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer (2006) (126)
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer (2013) (123)
Intra‐abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer (2009) (122)
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance (2015) (122)
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study (2014) (119)
Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells (2005) (116)
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy (2009) (111)
Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma (2002) (110)
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
Polo-like kinase 1 expression is a prognostic factor in human colon cancer. (2005) (108)
Prognostic Relevance of AGR2 Expression in Breast Cancer (2006) (107)
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. (2010) (106)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. (2020) (106)
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) (104)
A prognostic gene expression index in ovarian cancer—validation across different independent data sets (2009) (104)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. (2021) (104)
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference (2003) (103)
Glutamate enrichment as new diagnostic opportunity in breast cancer (2015) (103)
Multicentre validation study of nucleic acids extraction from FFPE tissues (2010) (101)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2016) (100)
Tumor infiltrating lymphocytes in early breast cancer. (2018) (96)
Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression (2009) (96)
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery (2012) (95)
mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. (2011) (95)
Classical pathology and mutational load of breast cancer – integration of two worlds (2015) (93)
Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay (2012) (93)
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo (2009) (92)
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (2021) (90)
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) (90)
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance (2005) (89)
Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer (2011) (87)
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials (2015) (85)
Prognostic impact of cyclooxygenase-2 in breast cancer. (2004) (84)
Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274) – associations with gene expression, mutational load, and survival (2016) (83)
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. (2011) (83)
Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study (2014) (83)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer (2018) (80)
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. (2019) (79)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
Loss of Gelsolin expression in human ovarian carcinomas. (2005) (77)
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro (2009) (77)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial (2021) (76)
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. (2012) (75)
Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy (2015) (75)
Recommendations for collection and handling of specimens from group breast cancer clinical trials. (2008) (75)
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. (2008) (75)
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions (2013) (74)
Applying in-silico retention index and mass spectra matching for identification of unknown metabolites in accurate mass GC-TOF mass spectrometry. (2011) (74)
Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. (2003) (74)
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test (2012) (73)
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients (2014) (71)
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. (2019) (71)
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2015) (70)
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer (2018) (70)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). (2020) (68)
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast (2016) (67)
Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. (2010) (67)
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer (2013) (67)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). (2021) (67)
Uterine Arterial Embolization With Tris-acryl Gelatin Microspheres: A Histopathologic Evaluation (2005) (66)
Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. (2002) (66)
Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. (2016) (65)
Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers (2011) (65)
What turns CREB on? And off? And why does it matter? (2020) (65)
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response (2017) (64)
RANK expression as a prognostic and predictive marker in breast cancer (2014) (64)
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial (2016) (64)
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer (2014) (63)
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance (2013) (63)
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. (2017) (62)
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes (2014) (62)
Morphological and molecular breast cancer profiling through explainable machine learning (2021) (62)
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer (2018) (61)
Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic Cancer (2005) (61)
Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion (2002) (61)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). (2014) (59)
Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin (2012) (59)
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer (2015) (59)
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) (2011) (58)
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences (2014) (58)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) (58)
An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells (2004) (57)
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium (2013) (57)
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). (2017) (56)
Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. (2008) (56)
pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. (2017) (56)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
Analysis of PIK3CA Mutations in Breast Cancer Subtypes (2014) (54)
Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer (2012) (53)
Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. (2007) (53)
The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. (2021) (51)
Molecular HPV Typing as a Diagnostic Tool to Discriminate Primary From Metastatic Squamous Cell Carcinoma of the Lung (2009) (51)
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden (2018) (51)
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy (2016) (50)
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer (2015) (49)
S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. (2011) (49)
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma (2017) (49)
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. (2015) (48)
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. (2007) (48)
Expression patterns of polo‐like kinase 1 in human gastric cancer (2006) (48)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. (2011) (48)
Down‐regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer (2012) (47)
MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods (2018) (45)
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. (2016) (45)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2018) (44)
A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52) (2015) (44)
High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism (2017) (44)
CD 24 Expression Is a New Prognostic Marker in Breast Cancer (2003) (44)
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium (2012) (44)
Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) (2013) (43)
Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology. (2010) (43)
Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers (2014) (43)
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. (2015) (42)
SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. (2017) (42)
Neoadjuvant treatment of breast cancer--Clinical and research perspective. (2015) (42)
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. (2017) (42)
CognitionMaster: an object-based image analysis framework (2013) (42)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2019) (42)
Systematic Evaluation of the Intraoperative Tumor Pattern in Patients With Borderline Tumor of the Ovary (2009) (41)
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. (2016) (41)
Does long‐term survival in patients with pancreatic cancer really exist?—Results from the CONKO‐001 study (2013) (41)
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients (2014) (40)
Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany (2007) (40)
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer (2018) (40)
Loss-of-function uORF mutations in human malignancies (2018) (40)
Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. (2013) (40)
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) (2015) (39)
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) (2012) (39)
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance (2016) (39)
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer (2016) (38)
Intraductal papillomas of the breast: diagnosis and management of 151 patients. (2011) (38)
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. (2006) (38)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). (2018) (38)
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment (2021) (38)
Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections (2012) (38)
KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma (2014) (37)
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. (2019) (36)
Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. (2009) (36)
New network topology approaches reveal differential correlation patterns in breast cancer (2013) (35)
High nuclear poly‐(ADP‐ribose)‐polymerase expression is prognostic of improved survival in pancreatic cancer (2012) (35)
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. (2014) (35)
Resistance to chemotherapy in ovarian carcinoma. (2007) (34)
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H (2019) (34)
Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors (2017) (34)
Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer (2006) (34)
Expression of classical NF‐κB pathway effectors in human ovarian carcinoma (2010) (34)
Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy (2016) (34)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types (2017) (33)
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer (2016) (33)
Disseminated Mucormycosis Caused by Absidia corymbifera Leading to Cerebral Vasculitis (2000) (33)
An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas (2011) (33)
The immunogenicity of breast cancer--molecular subtypes matter. (2014) (32)
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. (2019) (32)
Genome-wide Gene Expression Profiling of Formalin-fixed Paraffin-Embedded Breast Cancer Core Biopsies Using Microarrays (2011) (32)
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (32)
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. (2016) (31)
Expression of multidrug resistance‐associated protein 1 in invasive ovarian carcinoma: implication for prognosis (2009) (31)
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status (2006) (31)
Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis (2009) (31)
Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (2019) (31)
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. (2013) (30)
DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer (2019) (30)
Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. (2016) (30)
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). (2017) (30)
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. (2020) (30)
Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66) (2013) (29)
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer (2013) (29)
Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines (1999) (29)
Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. (2011) (29)
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype (2019) (29)
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer (2014) (29)
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
Vascular CXCR4 Expression – a Novel Antiangiogenic Target in Gastric Cancer? (2010) (29)
Overexpression of cyclooxygenase‐2 in human prostate carcinoma and prostatic intraepithelial neoplasia‐association with increased expression of polo‐like kinase‐1 (2007) (29)
Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. (2003) (28)
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. (2021) (28)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial (2018) (28)
Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (27)
Interleukin-10 in serous ovarian carcinoma cell lines (2001) (27)
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. (2019) (27)
Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer (2014) (27)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer (2018) (27)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
Towards computational fluorescence microscopy: Machine learning-based integrated prediction of morphological and molecular tumor profiles (2018) (26)
Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger (2012) (26)
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice (2019) (26)
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma (2018) (26)
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. (2021) (26)
Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis (2005) (25)
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). (2016) (25)
Abstract S1-09: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients (2017) (25)
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials (2019) (24)
Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche (2021) (24)
IMP3 Expression in Human Ovarian Cancer is Associated With Improved Survival (2009) (24)
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. (2015) (24)
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. (2013) (24)
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy (2011) (24)
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. (2020) (23)
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer1 (2018) (23)
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. (2021) (23)
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. (2021) (23)
Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma (2012) (22)
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer (2019) (22)
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2020) (22)
Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years (2017) (22)
Evaluation of a hormone receptor‐positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin‐fixed paraffin‐embedded tissue (2011) (22)
Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 (2018) (21)
S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab. (2011) (21)
Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort. (2021) (21)
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. (2016) (21)
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. (2022) (21)
Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment (2016) (21)
cancerclass: An R Package for Development and Validation of Diagnostic Tests from High-Dimensional Molecular Data (2014) (21)
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. (2009) (20)
Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-&kgr;B Pathway (2014) (20)
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. (2004) (20)
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy (2020) (20)
Reply to Ki67 in breast cancer: a useful prognostic marker! (2014) (19)
Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer (2014) (19)
Quantitative analysis of diagnostic guidelines for HER2-status assessment. (2012) (19)
A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. (2016) (19)
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial (2020) (19)
Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report. (2006) (19)
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. (2019) (18)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (18)
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer (2021) (18)
A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer (2020) (18)
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. (2005) (18)
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue (2009) (17)
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (17)
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. (2011) (17)
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer (2012) (17)
Induction of apoptosis in the centre of multicellular tumour spheroids of colorectal adenocarcinomas—involvement of CD95 pathway and differentiation (1998) (17)
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2019) (17)
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts (2011) (16)
Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer (2013) (16)
Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences (2020) (16)
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. (2021) (16)
Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. (2003) (16)
Linking CREB function with altered metabolism in murine fibroblast-based model cell lines (2017) (16)
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (16)
Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B (2021) (16)
Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX) (2013) (15)
Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology (2017) (15)
Abstract PD02-06: New Molecular Biomarkers for Resistance to Trastuzumab in Primary HER2 Positive Breast Cancer — A Translational Investigation from the Neoadjuvant GeparQuattro Study (2010) (15)
Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer (2014) (15)
The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer. (2006) (15)
Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. (2006) (15)
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. (2022) (15)
A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer (2019) (14)
A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). (2015) (14)
Tumor-infiltrating lymphocytes in breast cancer (2014) (14)
Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer (2020) (13)
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2018) (13)
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). (2012) (13)
Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer (2013) (13)
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer (2020) (13)
Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer (2019) (13)
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). (2017) (13)
Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma (2015) (13)
Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium (2014) (13)
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) (12)
443 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy (2010) (12)
Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer. (2013) (12)
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) (12)
Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies (2013) (12)
Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival (2018) (12)
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer (2018) (12)
Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining (2019) (12)
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial (2020) (12)
Adhesion and Migration of HRT-18 Colorectal Carcinoma Cells on Extracellular Matrix Components Typical for the Desmoplastic Stroma of Colorectal Adenocarcinomas (2003) (12)
Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial) (2018) (11)
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial (2015) (11)
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. (2019) (11)
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases (2020) (11)
Preoperative transvaginal ultrasound (TVS) in the description of pelvic tumor spread in endometrial cancer: results of a prospective study. (2008) (11)
Value of preoperative transvaginal sonography (TVS) in the description of tumor pattern in ovarian cancer patients: results of a prospective study. (2007) (11)
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization (2016) (11)
Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC) (2019) (11)
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. (2021) (10)
[Update of the German S3 breast cancer guideline : What is new for pathologists?] (2019) (10)
PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. (2010) (10)
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study (2021) (10)
Borderline tumors of the ovary and peritoneal implants. (2005) (10)
Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. (2019) (10)
Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. (2015) (10)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. (2017) (9)
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) (9)
Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database (2019) (9)
Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression. (2014) (9)
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor (2018) (9)
Breast cancer, locally advanced and metastatic (2012) (9)
Abstract OT3-3-11: A RANDOMIZED PHASE III TRIAL COMPARING NANOPARTICLE-BASED PACLITAXEL WITH SOLVENT-BASED PACLITAXEL AS PART OF NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH EARLY BREAST CANCER (GeparSepto) GBG 69 (2012) (9)
HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network. (2013) (9)
Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. (2014) (8)
Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research (2010) (8)
Imatinib – eine mögliche Therapieoption beim Zervixkarzinom: Ergebnisse einer präklinischen Phase-I-Studie (2008) (8)
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. (2019) (8)
Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (2012) (8)
Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial. (2014) (8)
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast (2021) (8)
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial (2022) (8)
Fulminant intravascular disseminating malignant melanoma mimicking acute leukemia. (1999) (8)
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. (2008) (7)
Ki 67 measured after neoadjuvant chemotherapy for primary breast cancer (2013) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (7)
Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. (2022) (7)
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses (2022) (7)
[Role of estrogen receptor-related receptors alpha, beta and gamma in ovarian cancer cells]. (2005) (7)
Abstract S4-5: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial (2012) (7)
Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies. (2013) (6)
Ligneous cervicitis in a woman with plasminogen deficiency associated with an atypical form of microglandular hyperplasia: a case report and review of literature. (2013) (6)
Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. (2017) (6)
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. (2019) (6)
MEK 1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer (2014) (6)
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium (2019) (6)
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (6)
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network (2017) (6)
Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment. (2009) (6)
[Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis]. (2018) (6)
[Molecular pathology for breast cancer: Importance of the gene expression profile]. (2015) (6)
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease (2021) (6)
Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study (2020) (6)
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. (2021) (6)
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) (6)
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) (6)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial (2020) (6)
Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker? (2021) (6)
Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial. (2017) (5)
Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database. (2019) (5)
[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]. (2007) (5)
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus (2021) (5)
DNA methylation-based classification of sinonasal tumors (2022) (5)
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis (2013) (5)
Aktualisierte WHO-Klassifikation der Tumoren der Mamma: Die wichtigsten Änderungen (2021) (5)
How VEGF-A and its splice variants affect breast cancer development – clinical implications (2022) (5)
Diagnostik und Therapie der Eisenmangelanämie in der Schwangerschaft und postpartal (2008) (5)
233TiPKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) (2017) (5)
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. (2022) (5)
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial (2020) (5)
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. (2021) (5)
Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. (2012) (5)
Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment (2021) (5)
How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer? (2017) (5)
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer (2012) (5)
Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. (2022) (5)
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. (2021) (5)
Semiconductor sequencing: how many flows do you need? (2015) (5)
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) (5)
Abstract OT2-02-01: Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The intergroup-sentinel-mamma (INSEMA)-trial (2016) (5)
[New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis]. (2022) (4)
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2020) (4)
[Updated WHO classification of tumors of the breast: the most important changes]. (2021) (4)
SPARC in pancreatic cancer: Results from the CONKO-001 study. (2013) (4)
Selecting patients with HER2-low breast cancer: Getting out of the tangle. (2022) (4)
Molekulare Pathologie beim Mammakarzinom (2015) (4)
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group (2021) (4)
GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2019) (4)
Applicability of a System for Fully Automated Nucleic Acid Extraction From Formalin-fixed Paraffin-embedded Sections for Routine KRAS Mutation Testing (2012) (4)
Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. (2022) (4)
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy (2018) (4)
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores (2020) (4)
[Compliance of patients concerning recommended radiotherapy in breast cancer : Association with recurrence, age, and hormonal therapy]. (2012) (4)
1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) (4)
217OA gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy (2017) (4)
Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. (2019) (4)
Compliance der Patientinnen in Bezug zur empfohlenen Strahlentherapie beim Mammakarzinom (2012) (4)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply. (2021) (3)
Endoscopic ultrasound-fine needle biopsies of pancreatic lesions: Prospective study of histology quality using Franseen needle (2020) (3)
Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling. (2022) (3)
Abstract PD2-2: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT) (2013) (3)
Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer (2017) (3)
Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2020) (3)
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry (2022) (3)
Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium (2014) (3)
PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis. (2019) (3)
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes (2014) (3)
Post‐neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage‐ and regression‐grade independent prognostic information in intestinal‐type gastric adenocarcinoma (2022) (3)
METAtarget - Extracting Key Enzymes of Metabolic Regulation from Highthroughput Metabolomics Data using KEGG REACTION Information (2010) (3)
Acute myocardial infarction caused by coronary tumor thromboembolism: a rare primary manifestation of malignant tumor disease. (2006) (3)
Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (2019) (3)
Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) (2017) (3)
Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker? (2015) (3)
Abstract PD06-01: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort (2012) (3)
Abstract S3-01: EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS) (2016) (3)
Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). (2019) (3)
Molekulares Profiling und prädiktive Signaturen (2008) (3)
Das ER-positive, HER2-negative Mammakarzinom – Der EndoPredict®-Test hilft bei der Entscheidung über die endokrine Therapie +/- Zytostase (2012) (3)
Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom (2018) (3)
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). (2021) (3)
Update der S3-Leitlinie Mammakarzinom (2019) (3)
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression (2013) (3)
Establishment of a new valid animal model for the evaluation of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric rhabdomyosarcoma (2021) (3)
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers. (2022) (2)
Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". (2019) (2)
Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups (2021) (2)
Zytoplasmatische Überexpression von ALCAM – ein neuer Prognosemarker bei Brustkrebs (2005) (2)
Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC). (2018) (2)
Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. (2019) (2)
[Predictive molecular diagnostics in breast cancer : What are the requirements for pathology today and in the future?] (2022) (2)
737PTP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study (2017) (2)
199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) (2)
P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2−Negative Breast Cancer. (2011) (2)
Management von Borderlinetumoren des Ovars (BOT) (2005) (2)
Validated 3 Gene Signature Predicts Response to Neo-Adjuvant Chemotherapy in Luminal Breast Cancer – Results from GeparTrio and GeparQuattro. (2009) (2)
Analyzing the Immunological Landscape of a Tumor—Heterogeneity of Immune Infiltrates in Breast Cancer as a New Prognostic Indicator (2018) (2)
Abstract OT1-12-03: RESCUE: Reaching for Evidence-baSed Chemotherapy Use in Endocrine sensitive breast cancer - A prospective health care study on risk assessment by the clinicomolecular test EndoPredict®and long-term patient outcome in early luminal breast cancer (2019) (2)
176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) (2)
PG 7.04 Developing Ki67 as a useful marker (2015) (2)
[Preoperative chemotherapy in breast cancer and the development of new predictive markers]. (2006) (2)
168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) (2)
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX). (2016) (2)
8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy (2012) (2)
Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis. (2018) (2)
RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. (2011) (2)
Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data (2018) (2)
PD-007CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial (2016) (2)
Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival (2015) (2)
Pathological Workup of Surgical Breast Cancer Specimens after Neoadjuvant Chemotherapy (2006) (2)
160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) (2020) (2)
Expression of the ELAV-like protein HuR in human colon cancer - association with cyclooxygenase-2 (COX-2) (2005) (2)
Konzept der prädiktiven Molekularpathologie (2011) (2)
Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma (2017) (2)
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board (2022) (2)
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). (2017) (2)
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). (2011) (2)
Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). (2015) (2)
135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) (2)
Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis (2021) (2)
Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. (2010) (2)
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. (2018) (2)
Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences (2021) (2)
New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis. (2022) (2)
Abstract 5573: GC-TOF mass spectroscopy reveals strong dependence of breast cancer metabolome on estrogene receptor, but not on HER2 status (2010) (2)
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium (2013) (2)
Gemcitabine: results from the CONKO-001 study (2014) (2)
Reply to F. Bellati et al (2010) (1)
Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. (2011) (1)
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (1)
Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (2018) (1)
[Molecular profiling and predictive signatures. Biomarker analysis in ovarian cancer]. (2008) (1)
127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo (2020) (1)
255ODUAL BLOCKADE WITH AFATINIB AND TRASTUZUMAB AS NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR OPERABLE BREAST CANCER RECEIVING TAXANE-ANTHRACYCLINE CONTAINING CHEMOTHERAPY (DAFNE)-GBG70 - EFFICACY AND SAFETY ANALYSIS. (2014) (1)
Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze) (2020) (1)
Abstract 4806: Association of changes in 4-aminobutyrate aminotransferase (ABAT) and beta-alanine metabolism with breast cancer and the more aggressive estrogen receptor negative subtype (2012) (1)
Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International (2017) (1)
In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. (2018) (1)
Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. (2017) (1)
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard). (2019) (1)
Characteristics of patients with brain metastases from HER2-positive breast cancer (2021) (1)
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium (2012) (1)
KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (2019) (1)
Hormone receptor-dependent regulation of ABAT and beta-alanine metabolism in breast cancer. (2013) (1)
Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial. (2017) (1)
Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials. (2016) (1)
Abstract P1-08-25: RANK expression is prognostic and predictive in primary breast carcinoma: Analysis of samples from the GeparTrio study (2013) (1)
Abstract P3-06-05: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. (2012) (1)
Endoskopische Vollwandresektion („endoscopic full-thickness resection“, eFTR) für kolorektale Läsionen – eine retrospektive Analyse von 38 konsekutiven Fällen (2019) (1)
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) (2022) (1)
Class I HDAC expression patterns are highly prognostic in human gastric cancer (2008) (1)
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test (2012) (1)
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2019) (1)
48P Comparison of an Rna-Based Multigene Test Between Core Biopsies and Corresponding Surgical Breast Cancer Sections (2012) (1)
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer. (2022) (1)
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens (2017) (1)
Ki67 as a prognostic factor in low grade serous ovarian cancer (LGSOC): A retrospective analysis of the Tumor Bank Ovarian Cancer (TOC). (2017) (1)
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood (2022) (1)
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer (2014) (1)
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer (2022) (1)
Detection and diagnosis (2012) (1)
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. (2022) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
Front Cover: MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods (2019) (1)
A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. (2017) (1)
Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. (2012) (1)
Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. (2011) (1)
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. (2016) (1)
Abstract P2-09-03: Antitumor activity of the glutaminase inhibitor, CB-839, in triple-negative breast cancer (2013) (1)
Abstract P1-14-11: nab-paclitaxel at a dose of 125 mg/m2weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2016) (1)
Applicability of a System for Fully Automated Nucleic Acid Extraction From Formalin-Fixed, Paraffin-Embedded Sections for Routine KRAS Mutation Testing (2012) (1)
Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies. (2019) (1)
Reply to L. Ozretić et al (2011) (1)
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype (2019) (1)
Abstract P3-06-36: Assessment of phosphorylated HER2 protein as predictive biomarker to stratify anti-HER2 treatment in HER2 non-amplified patients – A translational study in the GeparQuattro and GeparQuinto trials (2015) (1)
Tumor infiltrating lymphocytes (TILs) as prognostic biomarker in patients with breast cancer (2021) (1)
Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma (2022) (1)
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) (1)
0148 REACT study: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (2009) (1)
Abstract OT1-1-13: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 (2012) (1)
Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia (2022) (1)
Abstract P3-06-12: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial (2015) (1)
Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. (2021) (1)
30PTargeted mRNA sequencing of small formalin-fixed and paraffin-embedded breast cancer samples for the quantification of immune and cancer-related genes (2017) (1)
Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new, fully automated method for RNA isolation. (2009) (1)
Abstract P3-07-03:PIK3CAmutations predict resistance to trastuzumab/pertuzumab andnab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study (2016) (1)
Abstract 98: Automated cell tracking and interaction analysis in intra-vital two-photon microscopy image data (2010) (1)
Abstract 3128: mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumors (2010) (1)
Melanoma Expression of Cyclooxygenase 2 in Human Malignant (2000) (1)
Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. (2011) (1)
Automated Scoring of Nuclear Pleomorphism Spectrum with Pathologist-level Performance in Breast Cancer (2020) (1)
Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC) (2018) (1)
Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial. (2009) (1)
Abstract P2-08-10: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials (2019) (1)
Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2019) (1)
Preservation of Biomaterials for translational research in current breast cancer studies: Review and recommendations (2007) (1)
Immunological Mechanisms in Breast Cancer - from Bench to Bedside (2016) (1)
69PA NOVEL MULTIGENE ASSAY IN CLINICAL PRACTICE - PERFORMANCE AND IMPACT ON CLINICAL DECISIONS (2013) (1)
Prognostische Relevanz der Klasse I Histondeazetylasen beim Magenkarzinom (2008) (0)
Reply to Y. Kawamura et al. (2021) (0)
Abstract P3-05-03: Metaplastic breast cancers: Genomic profile, mutational burden and TILs (2018) (0)
Endoskopische Vollwandresektion („endoscopic full-thickness resection“, eFTR) für das frühe kolorektale Karzinom (CRC) - eine retrospektive Analyse von 31 konsekutiven Fällen (2021) (0)
Recent Publications in JSS (2014) (0)
2022-RA-1402-ESGO Implementing HRD testing in routine clinical practice among patients with primary high-grade advanced ovarian cancer (2022) (0)
Correction to "Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer─Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling". (2022) (0)
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) (0)
Title Page / Table of Contents (2019) (0)
EXPRESSION PATTERN OF HUMAN ESTROGEN RECEPTOR- RELATED RECEPTOR – ALFA-BETA, A SUB- FAMILY OF ORPHAN NUCLEAR RECEPTORS, AND THE ESTROGEN RECEPTOR ON HUMAN OVARIAN CANCER CELL LINES (2004) (0)
Abstract P5-07-02: Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results? (2016) (0)
Abstract P4-04-14: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study (2022) (0)
Abstract P4-06-01: Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial (2019) (0)
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer (2013) (0)
Editorial Board / Contents / Imprint (2018) (0)
[Gene expression analysis in breast cancer. A new diagnostic tool in pathology]. (2013) (0)
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials. (2019) (0)
Author Correction: Loss-of-function uORF mutations in human malignancies (2018) (0)
Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA (2022) (0)
Abstract P2-12-03: Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases (2022) (0)
Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study (2022) (0)
Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (2018) (0)
Prognostic score for Luminal A-like breast cancer patients. (2014) (0)
168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2022) (0)
Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. (2012) (0)
Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes. (2018) (0)
Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy. (2020) (0)
[Immunohistology in breast diagnostics : Strategies for efficient diagnostics]. (2022) (0)
Editorial Board / Contents / Imprint (2018) (0)
Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours (2022) (0)
46Pp53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial (2015) (0)
LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE) (2021) (0)
Abstract PS4-21: Comparison of risk assessment in primary ER+, HER2- Breast Cancer in a real-world data set: Classical pathological parameters vs. 12-gene molecular assay (EndoPredict) (2021) (0)
DNA-microarrays predicting chemotherapy response of malignant tumors (2005) (0)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (0)
Abstract 1220:PIK3CAmutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
Abstract 5682: Histomorphological and molecular immune classification of head and neck cancer and its relation to prognosis (2018) (0)
Editorial Board / Contents / Imprint (2017) (0)
SY 05 . 04 | Computer Aided Diagnosis Long-Term Application Of Automated Ki 67 Quantification In Routine Breast Cancer Diagnostics (2016) (0)
Editorial Board / Contents / Imprint (2018) (0)
Evaluation of tumor-associated lymphocytes as a predictor of response to neoadjuvant chemotherapy in breast cancer: Results from the GeparDuo and GeparTrio trial. (2009) (0)
Role of estrogen receptor-related receptors α, β and γ in ovarian cancer cells (2005) (0)
Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by combination with a photosensitive drug in pediatric rhabdomyosarcoma in an animal model (2022) (0)
Editorial Board / Contents / Imprint (2017) (0)
Editorial Board / Contents / Imprint / Contents of Forthcoming Issues (2016) (0)
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery (2012) (0)
Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69) (2017) (0)
Expression of gelsolin in ovarian carcinomas (2004) (0)
Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (2011) (0)
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (0)
68MO Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies (2022) (0)
Long-Term Application Of Automated Ki67 Quantification In Routine Breast Cancer Diagnostics (2016) (0)
Abstract 896: Serum-vascular endothelial growth factors (sVEGF) A and C have a potential as predictive tests for neoadjuvant bevacizumab in primary breast cancer (2014) (0)
Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers (2018) (0)
Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2017) (0)
Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study (2022) (0)
Prognostic value of epithelial cell adhesion molecule (EpCAM) in patients with primary epithelial ovarian cancer. (2012) (0)
Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer (2020) (0)
Patients with metastatic hormone receptor-positive breast cancer express PIK3CA oncogene mutational heterogeneity in circulating tumor cells (2016) (0)
Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (2018) (0)
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study (2022) (0)
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (0)
Estrogen receptor 1 mRNA expression as a strong prognostic factor in epithelial ovarian cancer patients treated with chemotherapy in the adjuvant and neoadjuvant setting (2008) (0)
Correlation between in vitro chemotherapy sensitivity and PARP-1 expression in patients with breast cancer. (2012) (0)
Rearranged Epstein-Barr Virus Genome in Hodgkin’s Disease and Angioimmunoblastic Lymphadenopathy: Swiss (2003) (0)
Abstract #746: Androgen-receptor expression in triple negative breast cancer: Results from the neoadjuvant GeparTrio trial (2009) (0)
269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry (2022) (0)
TITLE: INTEGRATED ANALYSIS OF PTEN AND p4EBP1 PROTEIN EXPRESSION AS PREDICTORs FOR pCR IN HER2 POSITIVE BREAST CANCER (2015) (0)
200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa (2022) (0)
Abstract P6-16-09: SPARC expression in brain metastases of breast cancer patients (2015) (0)
Molecular and Cellular Pathobiology Novel Theranostic OpportunitiesOffered byCharacterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression (2011) (0)
ADVANCED LUMINAL BREAST CANCER – PATHOLOGY, BIOLOGY AND RESISTANCE (2019) (0)
58PConcordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies (2015) (0)
Influence of cyclooxygenase-2 (COX-2) inhibition on the proliferation of ovarian cancer cell lines (2004) (0)
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) (0)
APOBEC 3 B protein expression and mRNA analyses in patients with 1 high-grade serous ovarian carcinoma 2 (2018) (0)
24PPhosphoproteomic assessment of HER2 signaling pathway in HER2 non-amplified patients of the GeparQuattro and GeparQuinto trials (2015) (0)
Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) (2015) (0)
Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease (2017) (0)
Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data (2018) (0)
Abstract 630: Detection of copy number variations in breast cancer using targeted sequencing without normal tissue controls (2015) (0)
149P Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores (2020) (0)
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict) (2021) (0)
ENDOSCOPIC FULL-THICKNESS RESECTION (EFTR) OF COLORECTAL LESIONS WITH THE FULL-THICKNESS RESECTION DEVICE (FTRD): A RETROSPECTIVE ANALYSIS OF 55 CONSECUTIVE CASES (2020) (0)
GC-TOF based metabolic profiling of human colon carcinoma (2007) (0)
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (0)
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) (0)
95MO Characteristics of patients with brain metastases from HER2-positive breast cancer (2021) (0)
Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1). (2018) (0)
2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs) (2022) (0)
[Prognostic role and regulation of cyclooxygenase-2 (COX-2) in ovarian carcinoma]. (2004) (0)
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference (2022) (0)
Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes. (2022) (0)
Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib (2022) (0)
[Clinically relevant molecular pathological diagnostics in breast cancer]. (2023) (0)
stress in advanced breast cancer Metabolic associations of reduced proliferation and oxidative Updated (2012) (0)
Abstract ES4-3: Tumor-infiltrating lymphocytes (TILs) and genomic signatures of immune cells (2017) (0)
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification (2022) (0)
Impact of Multifocal or Multicentric Disease on Surgical, Locoregional, and Distant Survival After Neoadjuvant Chemotherapy in 3562 Breast Cancer Patients (2012) (0)
Introduction on Genome-wide Expression Profiling from Formalin-Fixed Paraffin-Embedded Tissues Using Microarrays (2011) (0)
Editorial Board / Contents / Imprint (2018) (0)
Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene (2019) (0)
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices (2022) (0)
Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE). (2013) (0)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types (2017) (0)
Editorial Board / Contents / Imprint (2017) (0)
ESD RESECTION OF COLRECTAL PEDUNCULATED POLYPS: FIRST RESULTS (2022) (0)
Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study) (2016) (0)
RESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer. (2019) (0)
Editorial Board / Contents / Imprint (2016) (0)
Abstract P1-14-01: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. (2012) (0)
Abstract P6-03-06: Androgen supplementation in patient derived xenografts in androgen receptor positive breast cancer to increase engraftment and growth rate (2019) (0)
Heterogeneity in treatment response in patients with triple negative breast cancer (2019) (0)
39PDeciphering the connection of tumor genetics, tumor immune cell infiltration and prognosis in breast cancer (2017) (0)
Abstract P6-15-01: Withdrawn (2018) (0)
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) (0)
Abstract ES11-3: Novel approaches for selection of and monitoring treatment (2018) (0)
Editorial Board / Contents / Imprint (2016) (0)
66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) (0)
Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial (2020) (0)
Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis? Genexpressionsanalysen beim frühen Mammakarzinom – quo vadis? (2017) (0)
[Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer]. (2020) (0)
39OConstitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer (2015) (0)
Abstract P6-15-03: Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) (0)
Class IHistone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer : Specific Role of Class I Histone Deacetylases In vitro and In vivo (2008) (0)
21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) (0)
Low Positivity for Hormone Receptors in Early Breast Cancer: Therapy-Response and Prognosis -A Systematic Analysis of a Total of 9027 Patients (2019) (0)
Phenotypic and functional characteristics of patient derived murine xenograft models. (2019) (0)
Rescue: reaching for Evidence-baSed chemotherapy Use in ndocrine sensitive breast cancer – Eine prospektive Versorgungsstudie zum Outcome von Patienten mit durchgeführtem EndoPredict® Test zur Risikostratifizierung (2019) (0)
28P Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer (2020) (0)
Clinical and histological characteristics of peritoneal metastases of ILC (2018) (0)
Abstract P4-04-08: Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants (2020) (0)
Gallen-Konsensuskonferenz ( Wien 2017 ) Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International St . Gallen Breast Cancer Conference ( Vienna 2017 ) (2017) (0)
Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer (2022) (0)
151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts (2022) (0)
Predictive Biomarker of ER+/HER2- Breast Cancer - Discrepancies between German S3 Guideline, AGO Recommendation and St. Gallen Opinion of the Experts (2013) (0)
Regulation of lipid metabolism in breast cancer (2011) (0)
Reports of Oncological Societies (2014) (0)
106P Ultra low-coverage whole genome sequencing for precision oncology in solid tumors (2022) (0)
Abstract P3-08-01: Prognostic performance of EndoPredict in invasive lobular carcinoma (2018) (0)
What turns CREB on? And off? And why does it matter? (2020) (0)
Abstract P1-10-08: Assessing immune biomarkers of response to anthracyclines in breast cancer (2020) (0)
DNA-microarrays predicting chemotherapy response of ovarian carcinomas (2006) (0)
Abstract P1-07-01: HLA class I expression is associated with tumor-infiltrating lymphocytes and response and survival after neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer (2018) (0)
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup (2022) (0)
HR-MAS proton NMR based metabolomic analysis of breast cancer tissues highlight the importance of choline metabolites in tumour grading (2010) (0)
Abstract P3-07-55: Predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving carboplatin (2016) (0)
Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations (2020) (0)
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) (0)
94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) (0)
350 POSTER Chass I histone deacetylase isoforms in prostate cancer: expression patterns in vivo and functional implications in vitro (2006) (0)
Abstract P1-01-07: Clinical and histological characteristics of peritoneal metastases of invasive lobular breast cancer (2018) (0)
Differentially expressed genes in prostate cancer — identification of CD24 as a new prognostic marker (2004) (0)
24P Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) (0)
5177 POSTER Correlation Between PARP-1 Expression and ln-vitro Chemotherapy Sensitivity in Patients With Breast Cancer (2011) (0)
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2021) (0)
HDAC in gastric cancer: Expression patterns and prognostic implications (2008) (0)
Abstract 3709: Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types (2017) (0)
Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer (2022) (0)
Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer. (2018) (0)
12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients (2022) (0)
Abstract 1761: Class I HDAC expression patterns in gastroenteropancreatic neuroendocrine tumors (2010) (0)
Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. (2019) (0)
Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial (2017) (0)
Editorial Board / Contents / Imprint (2017) (0)
Deregulation of hydroxybutyric acid metabolism provides diagnostic and prognostic biomarkers in ovarian high-grade serous carcinomas (2016) (0)
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019) (0)
Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls (2017) (0)
Abstract 2913: Glutamate-enriched breast cancer as new entity and target for metabolic drugs (2014) (0)
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) (0)
Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by a combination with a photosensitive drug in pediatric rhabdomyosarcoma. (2021) (0)
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. (2022) (0)
Predictive Biomarkers and Personalized Medicine Ki67Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer (2013) (0)
Editorial Board / Contents / Imprint (2016) (0)
Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) (2018) (0)
A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting. (2017) (0)
Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials. (2016) (0)
Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer. (2014) (0)
Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading (2022) (0)
Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study (2012) (0)
ENDOSCOPIC FULL-THICKNESS RESECTION (EFTR) FOR EARLY COLORECTAL CARCINOMA (CRC) – A RETROSPECTIVE ANALYSIS OF 31 CONSECUTIVE CASES (2022) (0)
' s response to reviews Title : Gross cystic disease fluid protein 15 ( GCDFP-15 ) expression in breast cancer subtypes (2014) (0)
Abstract 2652: Pan-cancer analysis of programmed death-ligand 1 (PD-L1) amplifications (2016) (0)
Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC). (2018) (0)
Editorial Board / Contents / Imprint (2015) (0)
Radiofrequency Ablation of Liver Metastases from Colorectal Cancer Induces a Cancer-Specific T Cell Repertoire in Humans (2018) (0)
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging (2023) (0)
Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial (2019) (0)
Editorial Board / Contents / Imprint (2018) (0)
Front & Back Matter (2020) (0)
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma (2018) (0)
Corrections to "SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study". (2017) (0)
Abstract P4-10-16: Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer (2020) (0)
Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer (2022) (0)
Editorial Board / Contents / Imprint (2017) (0)
Expression of the ELAV-like protein HuR in ovarian carcinoma (2004) (0)
PIK3CA mutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
Gynecological Pathology, Abstract 362–379, Study Group (2003) (0)
Relevance of tumor infiltrating lymphocytes in patients with HER2 positive and triple negative breast cancer (2017) (0)
Abstract 5013: Rapid generation of phenomic and functional profiles of patient-derived 3D cell culture models for identification of treatment vulnerabilities of breast cancer: Early results of the EFRE-PoP project (2018) (0)
Editorial Board / Contents / Imprint (2017) (0)
Imatinib as a possible therapy option for cervical carcinoma (2008) (0)
Abstract P2-09-02: Blinded molecular subtyping analysis from RNA-Seq of FFPE samples in the GeparQuinto trial reveals predictive value of VEGFA metagene for bevacizumab treatment (2018) (0)
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer (2023) (0)
13INDIAGNOSTIC AND THERAPEUTIC IMPLICATIONS OF TUMOUR-INFILTRATING LYMPHOCYTES IN BREAST CANCER. (2014) (0)
21PExpression of CD138 / syndecan-1 in triple-negative breast cancer – correlative study of GeparSixto (2015) (0)
Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer (2023) (0)
Abstract P1-13-04: Higher rate of severe toxicities in obese patients receiving dose-dense chemotherapy according to unadjusted body mass index – Results of the prospectively randomized GAIN study (2016) (0)
Abstracts der 40. Arbeitstagung der Chirurgischen Arbeitsgemeinschaft Endokrinologie (CAEK) (2022) (0)
PiA – Prognose im Alltag; prospektive Erfassung von 1000 Patientinnen mit primärem Mammakarzinom an 5 Brustzentren (2011) (0)
Expression von PARP-1 beim Mammakarzinom korreliert mit einer gesteigerten in-vitro Chemotherapie-Sensitivität (2011) (0)
Eine mdm2 Genamplifikation ist mit Progression und Metastasierung des luminalen Mammakarzinoms im humanisierten Tumormausmodell (hPDX) assoziiert, sowie mit einem ungünstigen klinischen Verlauf der Erkrankung (2022) (0)
Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom (2023) (0)
Prädiktive molekulare Diagnostik beim Mammakarzinom (2022) (0)
Immunhistologie in der Mammadiagnostik (2022) (0)
Herzlichen Glückwunsch zum Geburtstag, lieber Herr Dietel! (2013) (0)
Immunonkologie und tumorinfiltrierende Lymphozyten – neue Strategien für Therapie und Diagnostik des Mammakarzinoms (2020) (0)
Aktuelle Aspekte zur Tumorigenese und Ätiologie (2014) (0)
Multigentests zur Risikoabschätzung beim frühen Mammakarzinom (2017) (0)
Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2 (2004) (0)
Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie (2021) (0)
Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens (2017) (0)
Ursachen der nicht durchgeführten Strahlentherapie beim Mammakarzinom, trotz Empfehlung der interdisziplinären Tumorkonferenz (2010) (0)
Aktuelle Aspekte der Diagnostik von Ovarialtumoren (2018) (0)
«Off label use» von Arzneimitteln in Gynäkologie und Geburtshilfe (2008) (0)
HRD-Testung und BRCA1/2-Keimbahntestung in der klinischen Routine bei Patientinnen mit primärem Ovarialkarzinom (2022) (0)
Genexpressionsanalysen beim Mammakarzinom (2013) (0)
Diagnostik und Therapie des triple-negativen Mammakarzinoms (TNBC) – Empfehlungen für die tägliche Routine (2019) (0)
Agnostische Tumortherapie – was ist das? (2021) (0)
Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom (2022) (0)
Erfolgreiche Etablierung von präklinischen Brustkrebsmodellen (2018) (0)
Charakteristika und Überlebensanalyse der Patienten mit asymptomatischen Hirnmetastasen eines Mammakarzinoms (2020) (0)
Prädiktive Biomarker beim ER+/HER2 – Mammakarzinom – Diskrepanz zwischen S3-Leitlinie, AGO-Empfehlung und St.-Gallen-Expertenmeinung (2013) (0)
Outcome von Mammakarzinomen mit schwach positiven Hormonrezeptoren: Eine bevölkerungsbezogene Analyse eines 15-Jahres-Kollektivs (2021) (0)
Histondeacetylasen im Mammakarzinom (2011) (0)
Expression der NF-kappaB-Untereinheit p65/RelA im Ovarialkarzinom (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Carsten Denkert?

Carsten Denkert is affiliated with the following schools:

University of Cambridge
Medical University of Vienna
Humboldt University of Berlin
Institute of Cancer Research
University of Marburg
Heinrich Heine University Düsseldorf
University of California, Los Angeles
Kiel University
Technical University of Munich
National University of Ireland
Tampere University
Tel Aviv University
University of Edinburgh

Carsten Denkert's Academic­Influence.com Rankings

Why Is Carsten Denkert Influential?

Carsten Denkert's Published Works

Published Works

What Schools Are Affiliated With Carsten Denkert?

Carsten Denkert's AcademicInfluence.com Rankings